Q-omics provides the consensus-scored PDS5A profile across patient tissues and cancer cell-line models. PDS5A expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, PDS5A is differentially expressed in 15, with the highest sampling consensus in STAD. Additionally, PDS5A protein abundance shows 26,188 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LGG, STAD, and GBM as cancer lineages where PDS5A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDS5A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDS5A survival associations across molecular data types. PDS5A RNA expression shows survival associations in the most cancer types (27), followed by mutation status (9) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDS5A RNA expression–survival associations across cancer types. High PDS5A expression shows unfavorable associations in LGG, UVM, LIHC and KICH, but favorable associations in KIRC and READ. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for PDS5A RNA expression.
This table summarizes PDS5A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PDS5A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDS5A shows higher tumor expression in STAD, KIRC, BLCA, KIRP, HNSC and LUAD. The STAD box plot shows higher PDS5A RNA expression in tumor versus normal tissue (log2 FC = +0.822, t-test p < 0.001).
This table shows molecular features associated with PDS5A in patient tissues and cancer cell lines. In patient samples, PDS5A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PDS5A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
